Gene Signature for Predicting Solid Tumors Patient Prognosis
Posted Mar 14 2011 8:00pm
Description of Invention: A progressive sequence of somatic mutations and epigenetic changes of oncogenes or tumor suppressor genes are believed to cause tumor development. However, high genomic instability in tumors causes the accumulation of genomic aberrations that do not contribute to tumor progression. Therefore it is important to distinguish between ‘driver’ mutations which are functionally important and ‘passenger’ mutations which do not provide a selective advantage to the tumor cells.
The current invention describes a driver gene signature for predicting survival in patients with solid malignancies including hepatocellular carcinoma (HCC) and breast cancer. The gene signature includes ten cancer-associated genes, and the NIH researchers further discovered that a decrease in DNA copy number or mRNA expression of some genes is associated with poor prognosis in HCC tumors and breast cancer, while a decrease in DNA copy number or mRNA expression of a few other genes is associated with good prognosis. They have also demonstrated that at least four of these cancer-associated genes are functional tumor suppressor genes. Thus, these genes may be potential molecular targets of HCC and breast cancer.
Available for licensing is a method of predicting the prognosis of a patient diagnosed with HCC or breast cancer by detecting expression of one or more cancer-associated genes, and a method of identifying an agent for use in treating HCC.
Applications:
Prognosis for hepatocellular carcinoma (HCC) and breast cancer patient survival.
Potential new method to identify therapeutic treatment for HCC and breast cancer patients.
Development Status: Early-stage development
Inventors: Xin Wei Wang (NCI) Stephanie K Roessler (NCI)
Patent Status: HHS, Reference No. E-024-2009/0 PCT, Application No. PCT/US2009/063883 filed 10 Nov 2009 which published as WO 2010/054379 on 14 May 2010
Licensing Status: Available for licensing.
Collaborative Research Opportunity: The National Cancer Institute, Center for Cancer Research, Laboratory of Human Carcinogenesis, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this Gene Signature for Predicting Hepatocellular Carcinoma Patient Prognosis. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
Portfolios: Cancer Cancer - Diagnostics Cancer - Therapeutics
For Licensing Information Please Contact: Betty Tong Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: tongb@mail.nih.gov Phone: 301-594-6565 Fax: 301-402-0220
Description of Invention:
A progressive sequence of somatic mutations and epigenetic changes of oncogenes or tumor suppressor genes are believed to cause tumor development. However, high genomic instability in tumors causes the accumulation of genomic aberrations that do not contribute to tumor progression. Therefore it is important to distinguish between ‘driver’ mutations which are functionally important and ‘passenger’ mutations which do not provide a selective advantage to the tumor cells.
The current invention describes a driver gene signature for predicting survival in patients with solid malignancies including hepatocellular carcinoma (HCC) and breast cancer. The gene signature includes ten cancer-associated genes, and the NIH researchers further discovered that a decrease in DNA copy number or mRNA expression of some genes is associated with poor prognosis in HCC tumors and breast cancer, while a decrease in DNA copy number or mRNA expression of a few other genes is associated with good prognosis. They have also demonstrated that at least four of these cancer-associated genes are functional tumor suppressor genes. Thus, these genes may be potential molecular targets of HCC and breast cancer.
Available for licensing is a method of predicting the prognosis of a patient diagnosed with HCC or breast cancer by detecting expression of one or more cancer-associated genes, and a method of identifying an agent for use in treating HCC.
Applications:
Development Status:
Early-stage development
Inventors:
Xin Wei Wang (NCI)
Stephanie K Roessler (NCI)
Patent Status:
HHS, Reference No. E-024-2009/0
PCT, Application No. PCT/US2009/063883 filed 10 Nov 2009 which published as WO 2010/054379 on 14 May 2010
Licensing Status:
Available for licensing.
Collaborative Research Opportunity:
The National Cancer Institute, Center for Cancer Research, Laboratory of Human Carcinogenesis, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this Gene Signature for Predicting Hepatocellular Carcinoma Patient Prognosis. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.
Portfolios:
Cancer
Cancer - Diagnostics
Cancer - Therapeutics
For Licensing Information Please Contact:
Betty Tong Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: tongb@mail.nih.gov
Phone: 301-594-6565
Fax: 301-402-0220
Ref No: 1904
Updated: 03/2011